Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East


Aeglea receives $21.5 million upfront with up to approximately $130 million in milestone payments and royalties in the mid-twenties Immedica obtains exclusive commercialization rights in Europe and several Middle Eastern countries Austin, Texas, and Stockholm, March 22, 2021 – Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics […]